OBJECTIVE:To probe into the efficacy and safety of febuxostat combined with allopurinol in treatment of chronic kidney disease accompanied with hypercuricemia. METHODS:186 patients with chronic kidney disease accompanied with hypercuricemia admitted into the People`s Hospital of Xinxian from Jan. 2014 to Jul. 2016 were selected and divided into observation group and control group via random number table, with 93 cases in each group. The control group was treated with allopurinol, while the observation group was given febuxostat combined with allopurinol. The clinical efficacy, levels of blood uric acid, serum creatinine, urea nitrogen, estimated value of glomerular filtration rate (eGFR) of two groups were observed, and the difference of incidence of adverse drug reactions between two groups were compared. RESULTS:The total effective rate of observation group (96.77%, 90/93) was significantly higher than that of the control group (86.02%, 80/93); after treatment, levels of blood uric acid, serum creatinine and urea nitrogen of observation group were significantly lower than those of the control group; 4 weeks,8 weeks,12 weeks,24 weeks after treatment, the eGFR of observation group was significantly lower than that of the control group, with statistically significant difference (P<0.05). There was no significant difference in the incidence of adverse reactions between two groups(P>0.05). CONCLUSIONS:The efficacy of febuxostat combined with allopurinol in treatment of chronic kidney disease accompanied with hypercuricemia is remarkable and taking effect rapidly, which can improve blood uric acid index.%目的:探讨非布司他联合别嘌醇治疗慢性肾脏病伴高尿酸血症的疗效与安全性.方法:选取2014年1月-2016年7月河南省新县人民医院收治的慢性肾脏病伴高尿酸血症患者186例作为研究对象,以随机数字表法分为观察组和对照组,每组93例.对照组患者给予别嘌醇治疗,观察组患者在对照组的基础上加用非布司他治疗.观察两组患者的临床疗效及血尿酸、血肌酐、尿素氮水平、肾小球滤过率估算值,比较两组患者不良反应发生情况的差异.结果:观察组患者的总有效率为96.77%(90/93),明显优于对照组的86.02%(80/93);治疗后,观察组患者血尿酸、血肌酐、尿素氮水平明显低于对照组;治疗4、8、12、24周后,观察组患者肾小球滤过率估算值明显低于对照组,差异均有统计学意义(P<0.05).两组患者不良反应发生率的差异无统计学意义(P>0.05).结论:非布司他联合别嘌醇治疗慢性肾脏病伴高尿酸血症的疗效显著,起效快,可改善患者血尿酸指标.
展开▼
